Get started
Author

Karoline Spaepen

Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
2007 · Malik E. Juweid, Sigrid Stroobants, et al. · Journal of Clinical Oncology · 1,326
PDF
Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
2001 · Karoline Spaepen, Sigrid Stroobants, et al. · Journal of Clinical Oncology · 462
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma
2002 · K. Spaepen, S. Stroobants, et al. · Annals of Oncology · 409
PDF
Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
2003 · Karoline Spaepen, Sigrid Stroobants, et al. · Blood · 224
[18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction?
2003 · Karoline Spaepen, Sigrid Stroobants, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 194
Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
2001 · Karoline Spaepen, Sigrid Stroobants, et al. · British Journal of Haematology · 168
PDF
Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients
2003 · Karoline Spaepen, Sigrid Stroobants, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 74
Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria
2007 · Lieselot Brepoels, Sigrid Stroobants, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 66
18FDG PET in oncology: The best and the worst (Review)
2006 · Tarik Belhocine, Karoline Spaepen, et al. · International Journal of Oncology · 64
PDF
Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria
2007 · Lieselot Brepoels, Sigrid Stroobants, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 43
Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy.
2007 · Lieselot Brepoels, Sigrid Stroobants, et al. · PubMed · 29
Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
2001 · K Spaepen, L Mortelmans · PubMed · 15
Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET
2008 · G. Moulin-Romsee, K. Spaepen, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 13
Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study
2020 · Nils Helsen, Tim Van den Wyngaert, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 12
PDF
Prognostic value of pretransplant positron emission tomography using fluorine-18 fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
2003 · Karoline Spaepen, Sigrid Stroobants, et al. · Journal of Nuclear Medicine · 6
Positron emission tomography with fluorodeoxyglucose after first line chemotherapy in Non Hodgkin's Lymphoma
2000 · Karoline Spaepen, Sigrid Stroobants, et al. · Journal of Nuclear Medicine · 5
Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin's lymphoma (NHL).
2001 · Karoline Spaepen, Sigrid Stroobants, et al. · Digital Access to Libraries · 4
Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy
2022 · Frederik Soffers, Nils Helsen, et al. · EJNMMI Research · 3
PDF
Ultra-late recurrences of gastro-intestinal carcinoma after primary resection: the mechanism of dormancy.
2013 · J F Janssens, M T'Syen, et al. · PubMed · 2
Hodgkin's lymphoma: Response assessment by revised international workshop criteria
2007 · Lieselot Brepoels, Sigrid Stroobants, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1
Early evaluation of tumour response to STI 571 with FDG-PET in patients with soft tissue sarcomas (STS)
2001 · S. Stroobants, J. Goeminne, et al. · European Journal of Cancer · 1
Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by revised international workshop criteria
2007 · Lieselot Brepoels, Sigrid Stroobants, et al. · European Journal of Nuclear Medicine and Molecular Imaging
Waarde van sequentiële botscintigrafie en wittebloedcellenscintigrafie bij de diagnose van geïnfecteerde totale heupprothese
2007 · GOFFIN K, DE CEUNINCK L, et al. · Tijdschrift voor Geneeskunde
Response assessment of aggressive and indolent non-Hodgkin's lymphoma by revised integrated international workshop criteria
2006 · Lieselot Brepoels, Sigrid Stroobants, et al. · Annals of Oncology
50. PET in oncology: the KU Leuven experience
2002 · L. Mortelmans, K. Spaepen, et al. · Nuclear Medicine Communications
Works count: 29
Citation count: 3,124
H-index: 13
I10-index: 14
Year
Topic
Type